Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 19/20 | 0.80 |
| ▸ | CA1 | P00915 | 18/20 | 0.80 |
| ▸ | CA2 | P00918 | 18/20 | 0.80 |
| ▸ | CA12 | O43570 | 9/20 | 0.80 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.77 |
| ▸ | CA7 | P43166 | 2/20 | 0.77 |
| ▸ | BTK | Q06187 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21151146 | 0.88 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21728989 | 0.88 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL10292504 | 0.87 | CA9 (1.00) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21282085 | 0.86 | CA9 (0.71) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21183301 | 0.86 | CA1 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL17245251 | 0.86 | CA1 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21282083 | 0.86 | CA1 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL22855043 | 0.86 | CA1 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL18475593 | 0.86 | CA9 (0.71) | CA9CA1CA2CA12CA14 | |
| SCHEMBL14163754 | 0.86 | CA9 (1.00) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381324-A1 | SMALL MOLECULE DRUG CONJUGATES | EIDGENOESSICHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2023-11-30 | — | — | US | disclosed |
| US-20210308269-A1 | Small Molecule Drug Conjugates | EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2021-10-07 | — | — | US | disclosed |
| EP-3424537-B1 | SMALL MOLECULE DRUG CONJUGATES | EIDGENOESSICHE TECHNISCHE HOCHSCHULE ZUERICH (CH) | 2021-01-13 | — | — | EP | disclosed |
| EP-3102241-B1 | SMALL MOLECULE DRUG CONJUGATES | EIDGENOESSICHE TECHNISCHE HOCHSCHULE ZUERICH (CH) | 2019-04-17 | — | — | EP | disclosed |
| EP-3424537-A1 | SMALL MOLECULE DRUG CONJUGATES | Eidgenössiche Technische Hochschule Zürich (CH) | 2019-01-09 | — | — | EP | disclosed |
| US-10016511-B2 | Small molecule drug conjugates | ETH ZURICH (CH) | 2018-07-10 | — | — | US | disclosed |
| US-9884122-B2 | Small molecule drug conjugates | ETH ZURICH (CH) | 2018-02-06 | — | — | US | disclosed |
| US-20170224831-A1 | Small Molecule Drug Conjugates | ETH ZURICH (CH) | 2017-08-10 | — | — | US | disclosed |
| US-20170035892-A1 | Small Molecule Drug Conjugates | ETH ZURICH (CH) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381324-A1 | SMALL MOLECULE DRUG CONJUGATES | CA9, CA12, CA2 | CA9 1/4885CA1 10/4885CA2 3/4885 |
| US-20210308269-A1 | Small Molecule Drug Conjugates | CA9, CA12, CA2 | CA9 1/4885CA1 10/4885CA2 3/4885 |
| US-20170035892-A1 | Small Molecule Drug Conjugates | CA9, CA11, CA4 | CA9 1/4885CA1 6/4885CA2 11/4885 |
| US-10016511-B2 | Small molecule drug conjugates | CA9, CA12, CA2 | CA9 1/4885CA1 10/4885CA2 3/4885 |
| US-20170224831-A1 | Small Molecule Drug Conjugates | CA9, CA12, CA2 | CA9 1/4885CA1 10/4885CA2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.